Merck announced the acquisition of Verona, while Recordati reported royalty earnings and Ligand Pharmaceuticals updated its CEO.
3 reports, 2 independent
Updated Aug 6
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Merck announced the acquisition of Verona, while Recordati reported royalty earnings and Ligand Pharmaceuticals updated its CEO.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Coverage
Newest first; wire copies grouped- GlobeNewswireLigand Reports Second Quarter 2025 Financial Results and Raises Guidance Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased
- Insider MonkeyVerona Pharma (VRNA) Jumps 125% YTD; Merck $10-Billion Acquisition Bolsters Sentiment We recently published 10 Stocks Exploded Over 100%; One Shockingly Soared 11,000%. Verona Pharma plc (NASDAQ:VRNA